Clinical Trial Update: An Open-Label Pilot Study of Qualia Senolytic Supplementation for the Attenuation of Systemic Inflammatory Cytokines [NA]

View source ↗

Summary

Open-label pilot study evaluating Qualia Senolytic supplements for attenuating systemic inflammatory cytokines. The study status is NOT_YET_RECRUITING.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Inflammation

Drugs mentioned

• Qualia Senolytic Supplement

Snippet

Sponsor: Qualia Life Sciences | Conditions: Inflammation | NA | Status: NOT_YET_RECRUITING